Intra-Cellular Therapies, Inc. provided earnings guidance for the full year 2024. For the year, the company expects CAPLYTA net product sales are expected to be $645 million to $675 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
67.21 USD | -5.62% | -7.37% | -5.93% |
05-07 | Sector Update: Health Care Stocks Steady Pre-Bell Tuesday | MT |
05-07 | Transcript : Intra-Cellular Therapies, Inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.93% | 7.52B | |
-2.35% | 89.33B | |
+4.08% | 41.19B | |
-14.78% | 31.87B | |
+53.68% | 24.52B | |
-15.14% | 15.68B | |
-8.63% | 12.34B | |
-40.39% | 12.23B | |
+6.22% | 8.83B | |
-6.43% | 8.28B |
- Stock Market
- Equities
- ITCI Stock
- News Intra-Cellular Therapies, Inc.
- Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2024